- Nachrichtendetail
-
13.05.2024 07:39:16 - dpa-AFX: *REGENERON: FDA ACCEPTS FOR PRIORITY REVIEW SBLA FOR DUPIXENT FOR CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS
Copyright(c) 2024 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
Copyright RTT News/dpa-AFX
| Name | WKN | Börse | Kurs | Datum/Zeit | Diff. | Diff. % | Geld | Brief | Erster | Schluss | |
|---|---|---|---|---|---|---|---|---|---|---|---|
 |
SANOFI SA INHABER EO 2 | 920657 | Frankfurt | 88,030 | 13.06.24 19:55:08 | -1,970 | -2,19% | 0,000 | 0,000 | 89,260 | 90,000 |
|
REGENERON PHARMAC.DL-,001 | 881535 | Frankfurt | 956,000 | 13.06.24 14:35:44 | +19,800 | +2,11% | 0,000 | 0,000 | 947,200 | 936,200 |
